6.75
+0.15
+(2.27%)
At close: April 15 at 8:05:43 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (1970) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (1970) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | -- |
| Avg. Estimate | 28.4M | 28.7M | 126.5M | -- |
| Low Estimate | 28.4M | 28.7M | 126.5M | -- |
| High Estimate | 28.4M | 28.7M | 126.5M | -- |
| Year Ago Sales | -- | -- | 105.76M | -- |
| Sales Growth (year/est) | -- | -- | 19.61% | -- |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (1970) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (1970) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| L9S.F | -- | -- | -- | -- |
| S&P 500 | 6.76% | 5.73% | 9.19% | 14.14% |
Related Tickers
D01.BE BELITE BIO INC. R
51.50
+1.98%
87S.MU Roivant Sciences Ltd
8.90
+1.78%
BH3.SG PTC Therapeutics Inc
38.80
+4.86%
9LB.DU Legend Biotech Corp
30.20
+7.09%
BH3.BE PTC Therapeutics Inc
41.20
+3.52%
87S.DU Roivant Sciences Ltd
8.78
-1.35%
DUL.SG Alnylam Pharmaceuticals Inc
209.60
-0.33%
ATQP.SG Vericel Corp
37.00
+2.21%
6XC.F Soleno Therapeutics, Inc.
59.15
+4.51%
41X.SG Ardelyx Inc
4.0540
-0.86%